Skip to main content
MENU
Program
Agenda
CE Information
Educational Supporters
App Instructions
Speakers
Exhibit & Sponsor
Plan Your Experience
New York
Los Angeles
Dallas | Myeloma Day
Media & PR
Press Information
Media Center
Rates
REGISTER NOW
Watch Video
More Debates & Deeper Analysis
Event Photos
Where Debate & Discussion Lead to Better Treatment
connect with us
Agenda
+
Available Dates
April 5-6 | New York City
July 27-28 | Los Angeles
May 11 | Myeloma Day | Dallas
May 11 | Myeloma Day | Dallas
|
View upcoming dates
REGISTER NOW
MENU
Agenda
April 5-6 | New York City
Available Dates
Register
April 5-6 | New York City
July 27-28 | Los Angeles
May 11 | Myeloma Day | Dallas
Friday April 05, 2024
8:00 AM – 8:05 AM
Welcome
Co-Chair
John Leonard
MD
8:05 AM – 8:20 AM
Session 1: Debate-Chemotherapy Based Approaches Are Best for Initial Therapy for Mantle Cell lymphoma
Speaker
Peter Martin
MD
8:20 AM – 8:35 AM
Session 1: Debate-Novel, “Non-Chemotherapy” Approaches Are Best for Initial Therapy for Mantle Cell Lymphoma
Speaker
Jia Ruan
MD, PhD
8:35 AM – 8:45 AM
Session 1: PANEL DISCUSSION
Moderator
John Leonard
MD
Panelist
Jia Ruan
MD, PhD
Peter Martin
MD
8:45 AM – 9:00 AM
Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive CAR-T Cell Therapy?
Speaker
Samuel Yamshon
MD
9:00 AM – 9:15 AM
Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive Novel Agents?
Speaker
Barbara Pro
MD
9:15 AM – 9:25 AM
Session 2: PANEL DISCUSSION
Moderator
John Leonard
MD
Panelist
Barbara Pro
MD
Samuel Yamshon
MD
9:25 AM – 9:55 AM
Session 3: Reevaluating Frontline Therapy and Beyond for Hodgkin Lymphoma: Strategies for Optimal Clinical Decision-Making and Targeted Therapy across Patient Groups
Speaker
Andrew Evens
DO, MBA, MSc
9:55 AM – 10:05 AM
Session 3: Post Session Survey and Q&A
Moderator
John Leonard
MD
Panelist
Andrew Evens
DO, MBA, MSc
10:05 AM – 10:15 AM
Exhibit Hall Break
10:15 AM – 11:15 AM
Non-CME Innovation Theater (Sponsored by Lilly USA, LLC)
11:15 AM – 11:45 AM
Session 4: Targeted Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Speaker
John Allan
MD
11:45 AM – 11:55 AM
Session 4: Post Session Survey and Q&A
Moderator
John Leonard
MD
Panelist
John Allan
MD
11:55 AM – 12:25 PM
Session 5: Evaluating Targeted Therapeutic Options in Relapsed/Refractory Follicular Lymphoma
Speaker
John Leonard
MD
12:25 PM – 12:35 PM
Session 5: Post Session Survey and Q&A
12:35 PM – 12:45 PM
Exhibit Hall Break
12:45 PM – 1:45 PM
Non-CME Innovation Theater (Sponsored by AbbVie Medical Affairs)
1:45 PM – 2:00 PM
Session 6: Debate- CAR-T Cells Should Be Rarely Used in Relapsed Follicular Lymphoma
Speaker
Peter Martin
MD
2:00 PM – 2:15 PM
Session 6: Debate- CAR-T Cells Should Be More Often Used in Relapsed Follicular Lymphoma
Speaker
Caron Jacobson
MD, MMSc
2:15 PM – 2:25 PM
Session 6: PANEL DISCUSSION
Moderator
John Leonard
MD
Panelist
Caron Jacobson
MD, MMSc
Peter Martin
MD
2:25 PM – 2:55 PM
Session 7: Case Discussions in Leukemia
Moderator
Jessica Altman
MD
Panelist
Amer Zeidan
MBBS, MHS
Elias Jabbour
MD
2:55 PM – 3:05 PM
Session 7: Post Session Survey and Q&A
Moderator
Jessica Altman
MD
Panelist
Elias Jabbour
MD
3:05 PM – 3:15 PM
Exhibit Hall Break
3:15 PM – 4:15 PM
Non-CME Innovation Theater (Sponsored by Bristol Myers Squibb)
4:15 PM – 4:30 PM
Session 8: Debate- The Right Treatment for R/R ALL Is –Monoclonal Antibody
Speaker
Elias Jabbour
MD
4:30 PM – 4:45 PM
Session 8: Debate- The Right Treatment for R/R ALL Is – CAR-T
Speaker
Jae Park
MD
4:45 PM – 4:55 PM
Session 8: PANEL DISCUSSION
Moderator
Jessica Altman
MD
Panelist
Elias Jabbour
MD
Jae Park
MD
4:55 PM – 5:10 PM
Session 9: Transplant considerations for MDS patients undergoing AlloHSCT
Speaker
Aditi Shastri
MD
5:10 PM – 5:25 PM
Session 9: Therapeutic Updates for higher risk MDS
Speaker
Amer Zeidan
MBBS, MHS
5:25 PM – 5:35 PM
Session 9: PANEL DISCUSSION
Moderator
Jessica Altman
MD
Panelist
Aditi Shastri
MD
Amer Zeidan
MBBS, MHS
Saturday April 06, 2024
8:40 AM – 8:45 AM
Welcome
Co-Chair
Jessica Altman
MD
8:45 AM – 9:00 AM
Session 10: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for IC - YES
Speaker
Kristen O'Dwyer
MD
9:00 AM – 9:15 AM
Session 10: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for IC - NO
Presenter
Jessica Altman
MD
9:15 AM – 9:25 AM
Session 10: PANEL DISCUSSION
Moderator
Jessica Altman
MD
Panelist
Kristen O'Dwyer
MD
9:25 AM – 9:55 AM
Session 11: Advancing Risk Stratification and Symptom Management in Patients with Low- and Intermediate-Risk Myelodysplastic Syndromes
Speaker
Aditi Shastri
MD
9:55 AM – 10:05 AM
Session 11- Post Session Survey and Q&A
Moderator
Jessica Altman
MD
Panelist
Aditi Shastri
MD
10:05 AM – 10:35 AM
Session 12: Case Discussions in Myeloma
Moderator
Joseph Mikhael
MD, MEd, FRCPC, FACP
Panelist
Gareth Morgan
MD PhD
Saad Usmani
MD MBA FACP FASCO
Speaker
Adriana Rossi
MD
10:35 AM – 10:45 AM
Session 12: Post Session Survey and Q&A
Moderator
Joseph Mikhael
MD, MEd, FRCPC, FACP
Panelist
Adriana Rossi
MD
Gareth Morgan
MD PhD
Saad Usmani
MD MBA FACP FASCO
10:45 AM – 11:15 AM
Exhibit Hall Break
11:15 AM – 11:30 AM
Session 13: Debate - Should Stem Cell Transplant Be Offered to Patients over 65 ? YES
Speaker
David Siegel
MD, PhD
11:30 AM – 11:45 AM
Session 13: Debate - Should Stem Cell Transplant Be Offered to Patients over 65? - NO
Speaker
Ashley Rosko
MD
11:45 AM – 11:55 AM
Session 13: PANEL DISCUSSION
Moderator
Joseph Mikhael
MD, MEd, FRCPC, FACP
Panelist
Ashley Rosko
MD
David Siegel
MD, PhD
11:55 AM – 12:25 PM
Session 14: Multiple Myeloma: Strategies to Optimize Frontline Treatment Selection
Presenter
Joseph Mikhael
MD, MEd, FRCPC, FACP
12:25 PM – 12:35 PM
Session 14: Post Session Survey and Q&A
Panelist
Joseph Mikhael
MD, MEd, FRCPC, FACP
12:35 PM – 12:45 PM
Exhibit Hall Break
12:45 PM – 1:45 PM
Non-CME Innovation Theater (Sponsored by Johnson & Johnson)
1:45 PM – 2:15 PM
Session 15: Relapsed/Refractory Multiple Myeloma: Essential Strategies to Optimize the Utility of Novel and Cellular Therapies
Presenter
Noa Biran
MD
2:15 PM – 2:25 PM
Session 15: Post Session Survey and Q&A
Panelist
Noa Biran
MD
2:25 PM – 2:40 PM
Session 16: Debate- MRD Should Guide Therapy - YES
Speaker
Gareth Morgan
MD PhD
2:40 PM – 2:55 PM
Session 16: Debate- MRD Should Guide Therapy - NO
Speaker
Joshua Richter
MD
2:55 PM – 3:05 PM
Session 16: PANEL DISCUSSION
Moderator
Joseph Mikhael
MD, MEd, FRCPC, FACP
Panelist
Gareth Morgan
MD PhD
Joshua Richter
MD
3:05 PM – 3:35 PM
Exhibit Hall Break
3:35 PM – 3:50 PM
Session 17: Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate - YES
Speaker
Andrew Yee
MD
3:50 PM – 4:05 PM
Session 17: Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate - NO
Speaker
Brea Lipe
MD
4:05 PM – 4:15 PM
Session 17: PANEL DISCUSSION
Moderator
Joseph Mikhael
MD, MEd, FRCPC, FACP
Panelist
Andrew Yee
MD
Brea Lipe
MD
4:15 PM – 4:30 PM
Session 18: Debate - CAR T Cell Therapy Should Be Used as Early as Possible - YES
Speaker
Saad Usmani
MD MBA FACP FASCO
4:30 PM – 4:45 PM
Session 18: Debate - CAR T Cell Therapy Should Be Used as Early as Possible - NO
Speaker
Noopur Raje
MD
4:45 PM – 4:55 PM
Session 18: PANEL DISCUSSION
Moderator
Joseph Mikhael
MD, MEd, FRCPC, FACP
Panelist
Noopur Raje
MD
Saad Usmani
MD MBA FACP FASCO
Questions?
Contact